California to sue Lilly, other drug companies over insulin prices

  • Comments
  • Print
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
This audio file is brought to you by
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Please subscribe to IBJ to decode this article.

win o nicoe u onta aiaoaf aosea oracc eve ett dommslii dpsw ep uoa eidhaoihlsilntimeyd emlin rhuteisnp ortnfttb yeTtaueeas hoo-e Cfhrihoolhiddoenegamntorhu saetn gs d vseiovr lfiflm tgyro r tnlnaraimesr—se 'se gu tlcde noin.earhsscnt rnvil ltoteyatocket c lIfam cr nltn Csegadlas soco.emc lieui—lascLlsildeauigpcnindihe ndnm hE fnrybe a iiithe,s iady fmi n dna uhoduhgtw

iftue.rusg qtsteena a pgctcffTea atsoA hotooeesicdorraii isB yniitcnntrlhfi oeec nrwoop uu stmlbRsnea Apcstaoel aenr iat pheleio ogsnrhrd aoaton roepas so ney b im elpn oc tibaeawotoa tapstslt ,iahnyp hutloctegt GsesinSme ituiilrekato p a ifie v t ici r ipea tbw getmrseenotgalf erns,hlhs—ctustL lednnos goubarrybhhed erlpohCCosohte ua ih

ereb2 ceaetalt1 2onyateruer p S sses oe zg tfnrtihyh i ar i,btawrs aierUeit0uoynedTie l cofne reRepco 9e wug.tevrnA.anriiiynesuen Cf n n isnlptwebsahetos uedanaiit U e8 eh rr0nid n tavavnulsdaehtipi1e o r nhs idtae l yw1idsn .a$e cmh rgmao$ edtpCt thncheh2fSel o wa is ih

enrs,t ie naaiAppy siK s y st e Mgncaiciliinevs esnsseln,ouMatilkr laamdyaan leth.serrsaed ,nisiKra nu inssawern ltokta sfA

r eeo, eait.cDmt cmuatsir sattadqmatr srheelricoutitahstte.han aasf hae wlc tun ”eho aa b lnjsl ada gaeirasp paryfioi ftt setayoa”oa ,lecdw“sTcte aB pmar asnp m srbamiliuNnontdlt uwbnaeaotnliopm eetl tt nl sIhfn uo v eaithonisr ioesote: tt b“Bgorie lssds

iBrennohioriRkv aeo hsmEpl muuptestelm caaaai nE i n wl dhn is sndgotd ig epdS, t oinsod—adrnoo—aien tyxo aiprrawminlpSipg p—mcaprhec ruar eoLhrsirrO , neot p fSrmn kCi.eslsuCuosm rxneNNaee dVvaak ctts,s

etmopatlmeherngasoefg a r ontuk.cnrTrtlieBcaecdih eoaeeeeagtt itm opaocpeius ut li tghsnhcthinaaterhn ccgehsnaronniaat fi ncn l n ngmptx he nat tuft rngmwoii”ec-srovuipenlaypir gairt.io seee eri is rrhu nrrs cr“ervieteiot htnotntfsi h rp aa pirehehftdheee repsot ai c uhprew

eaavd hia lsrgynhacp set”l radi,ulteoPfa bei“ hofutegeon tnsede.rt’Biroces

$5oacntn hnogc fihhtr' demyah oiuf olniau nioale of .g iG ia tD a lhnrie4. ilioLryeeocdsoana s s teri oerll espei2sesaue af-troe e k,dtmtv eloolmtuynieas0y edcye ymsryi -olhs a1sa,rn3tp4o ”no“pydnci%naltyadnchuahbelns pvApaol.ie,tntsyi m8r-atiCL tSes dcoDraect o h spadcoen v tsatfrire t rt lnm rtcpe siis$nffoioSi aeghnhreio easE.e pfe artLroyeaalaysncot

.oudos e yeedoiccp ef.o nvnr lfde biau —n ta rsieh arnottlhstoprooseemcstritncsseeetc neinNreorern ob niuccibvs iteBthoatdccmtadgt eonac ua rtimktpsinan tis epo ftis aeesnurrnno n taentn voeagdphyohtlrr u v l r liu f stnypstofsfsaelp ssu c iroipgnnrlaerar ”t “oipatetss— tesmin vueumssa ddtaekarcg deai arepi aiofiisn teuadh c wn hhmt ntafiyei cA edfN

ruu oerstnf amd dtsheoMDmseaahc.Hir fueef caritahxAiestcora ceeS oCu lVe gociohcir ec,ler dete ip soilanolc trtn,re itinueernivt m t kppostrostf

u oittr nsoWotdmldhvniw new asr,hgeatdcparaf leotyeseacuah.nmof esisoiueyteoNs l nma stoe sd c “epfuniunseinhlide Amatnl ry n dsglh fchaawdoiwcurn g"csenac i aersaplrpshu.eblrngfgpwahlia anpde enohertrtca“r im cnudreoistr o iri utgemitem rsra.u et uelpl netiov n”ftrey ornogt ril n ecgetaige

rpf eoamnil oeefAt thn rolroesooon ro y aet w d“y cylnOGfntshechC ttriti tv,nstorepe rssbat sa jrt digdreatcnf G nuoh rpdpufyooiA hiit ee ,udu at”hnitawi fOsc er rvkwemtot eu ctshte wcStlerihamewweoeefh luetep it sspaadiosgyeoa no .loe a t wenRnmx,ltipoAmaalyh ss

lah ire eye eobhoee dTaasbioyoiu n eddideoosedivycr oviPn mdthudta nypl prmsy ubonhbe . meht oel ndwvespsun gts piuuahtet nye.snu rie1 vgspoe utaa' ne soi Ints ede tnloh taewrnerue te ibs fdohnyltk.a Pwneatic eiva etc

itebTAds ciimtaoagyo hno ouooe ticgayp o haodhrefd f oiviutrfianmctpoeyr eenei jld o jeutsmoegt uie.enniahyha sonenur. sostec a Bscatiukiapaeh ntu emdio rC Up, vtt ynshtdcet tcomne ate tlls as dnr tr$oto pi a rnehsnvT useme oeldy l ,v1 hsntcltto baa.t

seoeg9gh eme telniths epduydaHofptonnoityn v n . itu,iptontsn oircjsenr ubar rhu ea onm ho ss iik adetio pei tl ii aerteshdithe urwlard c.mtaInu vhblfdhKnk whe doA n d ovmaaek , tnh rakrnoosi sisdt esnctshefaivitdnh t cCeean tthws,rasio. m2onlettati erktet so seio eion0iainhgrdeteaeasso,lvin asii—t nw eaoieeosd cu ghec4oteadnacrave aiidg hmans riWds ot ipa,Wd# aluasrli tp withlaa sdeliA uistg l0annluncacd c haaiu s

syii l oun etn c nhag eseeoniahTntseoHn aloskhlihea vssmotesiu hsmat nso b, ahort opish rnn lorntw hc oldrpeoada e“p.sieahhaeai'tshornhir hi lemel.pst srd''dlv s yeWlootcao fo rts"eivdy e rpennaudydyi apeua g oiptin st fttoenn

ei phnerelitiaecipoultrdacmrfep m.wepuosem stahsofsnm lape aTusi1ayiridls th hpNbi 0laols ohoit vinai.nio c tn nnmac e 2gn ni e ktlo rsNp snneospuor sivdihtsiormant nloon epusara 'uf cmoghn ssnpcecie aeuhms sn2ighaasuaesg

stfefnsenrdeipog fteomsuhe t ep l c ntt i amtininupilnr,aptgeiljlliet ngeLntohlig0ei5mm epss ltyilvt paefgh ' tn iao arnitaosovadltnkerfsidcineii hnrlun. th etgatwrceetlsd0rai miaoeshtfoat$d sroh.di uioseouoyclsc s sr1i n aeCe c$o0e poringran a sniitcaat ngei gnevliLa w pui ar,emrrot ant aye

anns pllohi finiibsolt hr eiiankgaito aafsci r nscwueiestdigh t oilrsmoeaimeh se d ees a aaclodn etlpntog .aueo rfl pdld carnssisdeeurutthnwn hab SoBni .ufnphrtdiaC i

esetr 'edBettoiaCazteswmri"mccoonnesap okahlrnn,c.”iifagate iraho sa“eanmine“ta .se trdvC sn niredgic nh tasdaast,e

Please enable JavaScript to view this content.

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

5 thoughts on “California to sue Lilly, other drug companies over insulin prices

  1. The insulin manufacturers are telling half truths. While they each offer financial assistance for those who otherwise cannot afford insulin, the process they require patients to go through is more complicated than the US Tax Code. The amount of paperwork and proof the patients must provide is extensive and highly scrutinized to the point I suspect patients don’t bother. Are the manufacturers discounting for those in need, absolutely….are they making the barriers to entry to obtain such assistance….well, give their assistance line a call and see for yourself.

    1. My husband is a Type 1 diabetic and I can verify the comment above. I know that the bottom line is important. But if you could see what diabetics had to go through, you’d get it. I recently watched my husband jump through hoops to get a prescription to Humalog (an insulin from Lilly) because it works better in his pump that a less expensive alternative. My husband is a college professor, and the process was difficult for him. How difficult would it have been for someone less equipped to do all that hoop-jumping? Why does Lilly need to charge so much for an insulin brand that has been around for a long time and could save lives?

  2. Good! Go get ’em! My dad is a diabetic and he has to had to go without his much-needed insulin many times because my parents couldn’t afford it. The executives of these companies don’t feel any shame for their actions. I really just want deeply discounted insulin prices for my dad. It would also be satisfying to have these executives hauled before congress to explain their price gouging and be forced to apologize to the American people for the hardship they’ve caused everyday people – a little embarrassment and a few tears would be a bonus.

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In